Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and… Grant US-11702399-B2 United States of America 18 Jul 2023
Method of treating cancer in a patient by administering an antibody which binds colony… Grant US-11542335-B2 United States of America 03 Jan 2023
Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1… Grant US-11498968-B2 United States of America 15 Nov 2022
Methods of treating epithelioid cell tumors comprising administering a composition… Grant US-10973806-B2 United States of America 13 Apr 2021
Antibodies against human CSF-1R and uses thereof Grant US-10287358-B2 United States of America 14 May 2019
Antibodies against human CSF-1R and uses thereof Grant US-10077314-B1 United States of America 18 Sep 2018
Antibodies against human CSF-1R and uses thereof Grant US-9879085-B2 United States of America 30 Jan 2018
ANTIBODIES AGAINST HUMAN CSF-1R FOR USE IN INDUCING LYMPHOCYTOSIS IN LYMPHOMAS OR… Application EP-3108897-A1 European Patent Office 28 Dec 2016
ANTIBODIES BINDING PREFERENTIALLY HUMAN CSF1R EXTRACELLULAR DOMAIN 4 AND THEIR USE Application EP-2949670-A1 European Patent Office 02 Dec 2015
COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF Application WO-2013132044-A1 World Intellectual Property Organisation (WIPO) 12 Sep 2013
ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF Application WO-2013087699-A1 World Intellectual Property Organisation (WIPO) 20 Jun 2013
ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF Application WO-2011131407-A1 World Intellectual Property Organisation (WIPO) 27 Oct 2011
ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF Application WO-2011107553-A1 World Intellectual Property Organisation (WIPO) 09 Sep 2011
ANTIBODIES BINDING PREFERENTIALLY HUMAN CSF1R EXTRACELLULAR DOMAIN 4 AND THEIR USE Application WO-2011070024-A1 World Intellectual Property Organisation (WIPO) 16 Jun 2011
CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE Application WO-2008144062-A1 World Intellectual Property Organisation (WIPO) 27 Nov 2008